The long-awaited return of Theory Lunch

September 28, 2010 § Leave a comment

This Friday, Oct 1: Warren Alpert 563, 12 noon.  Hooray!  See you there.

The schedule for the rest of the year is here.

Quantitative issues in designing anti-cancer protein drugs
Jeffrey Way
Advanced Technology Team
Wyss Institute, Harvard

Abstract
The problem of delivering proteins to specific target cells is particularly acute for treating solid tumors because, unlike other tissues, tumors have no lymph node drainage. Thus, large (and small) molecules enter tumors by diffusion and penetration is almost always poor. As a result, action of drugs on normal tissues can predominate, leading to unacceptable side effects. To address this problem, we have taken a quantitative approach to minimizing the action of protein drugs on non-target tissues.

Evolution modulates the quantitative characteristics of protein interactions and often uses combinations of weak interactions to achieve a particular specificity. We addressed how quantitative optimization might be used in the design of multidomain proteins, constructing fusion proteins between EGF and interferon-alpha (IFNa), the anti-tumor antibody MR1-1 and IFNa, and the anti-glycophorin antibody 10F7 and erythropoietin (Epo). The goal was to generate proteins in which the cell binding of an “activity element” (IFNa or Epo) was driven by prior binding of a “targeting element”. We connected these elements with a linker that allows each fusion partner to simultaneously bind their receptors on a cell surface, and incorporated mutations into the IFNa and Epo elements that progressively decrease the binding of these ligands to their receptors. When the activity element is appropriately mutated, the selectivity of the resulting fusion protein can be enhanced at least 10- to 20-fold compared to a fusion protein consisting of only wild-type elements. These results support a quantitative approach in the design of fusion proteins.

References

  • N D Taylor, J C Way, P A Silver, P Cironi, “Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity”, Protein Eng Des Sel 23:251-60 2010. PubMed
  • P Cironi, I A Swinburne, P A Silver, “Enhancement of cell type specificity by quantitative modulation of a chimeric ligand”, J Biol Chem 283:8469-76 2008. PubMed

Tagged: ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

What’s this?

You are currently reading The long-awaited return of Theory Lunch at It Takes 30.

meta

%d bloggers like this: